Mitochondrial Dysfunction in Neurodegeneration

Numerous toxins are known to interfere with mitochondrial respiratory chain function. Use has been made of these in the development of pesticides and herbicides, and accidental use in man has led to the development of animal models for human disease. The propensity for mitochondrial toxins to induce neuronal cell death may well reflect not only their metabolic pathways but also the sensitivity of neurons to inhibition of oxidative phosphorylation. Thus, the accidental exposure of humans to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine and to 3-nitropropionic acid has led to primate models of Parkinson's disease and Huntington's disease, respectively. These models were made all the more remarkable when identical biochemical deficiencies were identified in relevant areas of humans suffering from the respective idiopathic diseases. The place of complex I deficiency in Parkinson's disease remains undetermined, but there is recent evidence to suggest that, in some cases at least, it may play a primary role. The complex II/III deficiency in Huntington's disease is likely to be secondary and induced by other pathogenetic factors. The potential to intervene in the cascade of reactions involving mitochondrial dysfunction and cell death offers prospects for the development of new treatment strategies either for neuroprotection in prophylaxis or rescue.

[1]  R. Duvoisin,et al.  Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity , 1985, Neuroscience Letters.

[2]  K. Ohno,et al.  Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. , 1990, Biochemical and biophysical research communications.

[3]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[4]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[5]  K. Jellinger,et al.  Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect , 1990, Journal of neurochemistry.

[6]  R. Waring,et al.  Xenobiotic metabolism in Parkinson's disease , 1989, Neurology.

[7]  S. Dimauro,et al.  An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region , 1989, Nature.

[8]  Patrizia Mecocci,et al.  Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease , 1994, Annals of neurology.

[9]  T. Chase,et al.  Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease , 1992, Movement disorders : official journal of the Movement Disorder Society.

[10]  F. Jiménez-Jiménez,et al.  Exposure to well water and pesticides in Parkinson's disease: A case‐control study in the madrid area , 1992, Movement disorders : official journal of the Movement Disorder Society.

[11]  J. Idle,et al.  Mutant debrisoquine hydroxylation genes in Parkinson's disease , 1992, The Lancet.

[12]  A. Novelli,et al.  Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced , 1988, Brain Research.

[13]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[14]  B. Summers,et al.  Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease , 1992, The Lancet.

[15]  C. Marsden,et al.  L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain , 1995, Movement disorders : official journal of the Movement Disorder Society.

[16]  Y. Mizuno,et al.  Apoptosis is induced by 1-methyl-4-phenylpyridinium ion (MPP+) in ventral mesencephalic-striatal co-culture in rat , 1994, Neuroscience Letters.

[17]  B T Hyman,et al.  Functional Alterations in Alzheimer's Disease: Diminution of Cytochrome Oxidase in the Hippocampal Formation , 1993, Journal of neuropathology and experimental neurology.

[18]  L. Sayre,et al.  Model study on the bioreduction of paraquat, MPP+, and analogs. Evidence against a "redox cycling" mechanism in MPTP neurotoxicity. , 1987, Biochemical and biophysical research communications.

[19]  R. Uitti,et al.  Geography, Drinking Water Chemistry, Pesticides and Herbicides and the Etiology of Parkinson's Disease , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[20]  Douglas C. Miller,et al.  A large kindred with autosomal dominant Parkinson's disease , 1990, Annals of neurology.

[21]  P. Jenner,et al.  Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine , 1993, Movement disorders : official journal of the Movement Disorder Society.

[22]  M. Dyer,et al.  Ultrastructural localization of bcl-2 protein. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  T. Niwa,et al.  Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. , 1987, Biochemical and biophysical research communications.

[24]  M J de Leon,et al.  Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. , 1992, Archives of neurology.

[25]  F. Hefti,et al.  Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture , 1990, Journal of neuroscience research.

[26]  P. Löschmann,et al.  Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.

[27]  C. Ward,et al.  Parkinson's disease in 65 pairs of twins and in a set of quadruplets , 1983, Neurology.

[28]  D B Calne,et al.  Progression after chronic manganese exposure , 1993, Neurology.

[29]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[30]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[31]  A. Schapira,et al.  Mitochondrial DNA analysis in Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[32]  G. Zeevalk,et al.  Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition. , 1991, The Journal of pharmacology and experimental therapeutics.

[33]  C. Epstein,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[35]  M. Beal,et al.  Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.

[36]  C. Marsden,et al.  Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.

[37]  B. Hyman,et al.  Functional Alterations in Alzheimer's Disease: Selective Loss of Mitochondrial-encoded Cytochrome Oxidase mRNA in the Hippocampal Formation , 1994, Journal of neuropathology and experimental neurology.

[38]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[39]  S. Paul,et al.  The N‐Methyl‐D‐Aspartate Antagonist MK‐801 Fails to Protect Dopaminergic Neurons from 1‐Methyl‐4‐ Phenylpyridinium Toxicity In Vitro , 1993, Journal of neurochemistry.

[40]  M. Graeber,et al.  Absence of the mitochondrial A7237T mutation in Parkinson's disease. , 1995, Biochemical and biophysical research communications.

[41]  E. Bertini,et al.  Fatal infantile liver failure associated with mitochondrial DNA depletion. , 1992, The Journal of pediatrics.

[42]  S. Markey,et al.  1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. , 1986, Life sciences.

[43]  C. Marsden,et al.  Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.

[44]  D. Neary,et al.  Mitochondrial function in brain tissue in primary degenerative dementia , 1987, Brain Research.

[45]  C. Olanow,et al.  Iron induces degeneration of nigrostriatal neurons , 1992, Brain Research Bulletin.

[46]  A. E. Harding,et al.  Parkinson's disease in twins studied with 18F‐dopa and positron emission tomography , 1992, Neurology.

[47]  C. W. Olanow,et al.  Manganese intoxication in the rhesus monkey , 1996, Neurology.

[48]  C. Marsden,et al.  Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1996, Neuroscience Letters.

[49]  C. Ragan,et al.  Photolabelling of a mitochondrially encoded subunit of NADH dehydrogenase with [3H]dihydrorotenone , 1987, FEBS letters.

[50]  Y. Mizuno,et al.  Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline , 1988, Neuroscience Letters.

[51]  P. Gill,et al.  Identification of the remains of the Romanov family by DNA analysis , 1994, Nature Genetics.

[52]  R. Uitti,et al.  Cyanide‐induced parkinsonism , 1985, Neurology.

[53]  B. Rosen,et al.  Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.

[54]  John Calvin Reed,et al.  Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA , 1993, Nature.

[55]  N. L. Rosenberg,et al.  Cyanide‐induced parkinsonism , 1989, Neurology.

[56]  R. Ramsay,et al.  Enhancement by tetraphenylboron of the interaction of the 1-methyl-4-phenylpyridinium ion (MPP+) with mitochondria. , 1989, Biochemical and biophysical research communications.

[57]  G. Zeevalk,et al.  MK‐801 Fails to Protect Against the Dopaminergic Neuropathology Produced by Systemic 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mice or Intranigral 1‐Methyl‐4‐Phenylpyridinium in Rats , 1992, Journal of neurochemistry.

[58]  C. Markham,et al.  Evidence to support early levodopa therapy in Parkinson disease , 1981, Neurology.

[59]  K. Jellinger,et al.  Mitochondrial DNA in Postmortem Brain from Patients with Parkinson's Disease , 1991, Journal of neurochemistry.

[60]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[61]  S. Fahn,et al.  Ascorbic acid protects against levodopa‐induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line , 1993, Movement disorders : official journal of the Movement Disorder Society.

[62]  R. Youle,et al.  Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. , 1991, Biochemical and biophysical research communications.

[63]  C. Marsden Parkinson's disease in twins. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[64]  S. Horai,et al.  Is Parkinson's disease a mitochondrial disorder? , 1992, Journal of the Neurological Sciences.

[65]  C. Marsden,et al.  Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1995, Biochemical pharmacology.

[66]  L. Massieu,et al.  Relationship of Dihydropyridine Binding Sites with Calcium‐Dependent Neurotransmitter Release in Synaptosomes , 1988, Journal of neurochemistry.

[67]  B. Rosen,et al.  Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.

[68]  R. Swerdlow,et al.  Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.

[69]  C. Marsden,et al.  A clinical and genetic study of familial Parkinson's disease , 1991, Movement disorders : official journal of the Movement Disorder Society.

[70]  C. Marsden,et al.  Mitochondrial respiratory chain function in multiple system atrophy , 1997, Movement disorders : official journal of the Movement Disorder Society.

[71]  J. Nobrega,et al.  Brain Cytochrome Oxidase in Alzheimer's Disease , 1992, Journal of neurochemistry.

[72]  D. Price,et al.  Age‐Dependent Impairment of Mitochondrial Function in Primate Brain , 1993, Journal of neurochemistry.

[73]  O. Phillipson,et al.  1, 2, 3, 4‐Tetrahydro‐2‐Methyl‐4, 6, 7‐Isoquinolinetriol Depletes Catecholamines in Rat Brain , 1993, Journal of neurochemistry.

[74]  K. Takeshige,et al.  NADH- and NADPH-dependent formation of superoxide anions by bovine heart submitochondrial particles and NADH-ubiquinone reductase preparation. , 1979, The Biochemical journal.

[75]  T. Niwa,et al.  Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes , 1990, Neuroscience Letters.

[76]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[77]  R. Clavier,et al.  Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l‐DOPA and Carbidopa Chronically , 1984, Journal of neurochemistry.

[78]  M. Beal,et al.  Cortical Cytochrome Oxidase Activity Is Reduced in Alzheimer's Disease , 1994, Journal of neurochemistry.

[79]  M. Naoi,et al.  Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains. , 1991, Biochemical and biophysical research communications.

[80]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[81]  R. Porter,et al.  Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum , 1993, Journal of neurochemistry.

[82]  J. Cooper,et al.  Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease , 1993, Brain Research.

[83]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[84]  E. Hurst EXPERIMENTAL DEMYELINATION OF THE CENTRAL NERVOUS SYSTEM: 3. POISONING WITH POTASSIUM CYANIDE, SODIUM AZIDE, HYDROXYLAMINE, NARCOTICS, CARBON MONOXIDE, ETC., WITH SOME CONSIDERATION OF BILATERAL NECROSIS OCCU , 1942 .

[85]  N. Castagnoli,et al.  Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. , 1984, Biochemical and biophysical research communications.

[86]  J. Haxby,et al.  Positron emission tomography in Alzheimer's disease , 1986, Neurology.

[87]  J. Cooper,et al.  Quantitation of a mitochondrial DNA deletion in Parkinson's disease , 1992, FEBS letters.

[88]  D. D. Di Monte,et al.  Blood lactate in Parkinson's disease , 1991, Annals of neurology.

[89]  A. Torroni,et al.  Mitochondrial oxidative phosphorylation defects in parkinson's disease , 1991, Annals of neurology.

[90]  H. Pall,et al.  N-methylation of pyridines in Parkinson's disease , 1991, The Lancet.

[91]  H. Yoshino,et al.  Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[92]  J. Drapier,et al.  Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. , 1988, Journal of immunology.

[93]  T. Chase,et al.  No evidence for altered muscle mitochondrial function in Parkinson's disease. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[94]  C. Marsden,et al.  A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.

[95]  S. Ohta,et al.  1‐Benzyl‐1,2,3,4‐Tetrahydroisoquinoline as a Parkinsonism‐Inducing Agent: A Novel Endogenous Amine in Mouse Brain and Parkinsonian CSF , 1995, Journal of neurochemistry.

[96]  Z. Rossetti,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. , 1988, Biochemical pharmacology.

[97]  A. Tolkovsky,et al.  The Death Programme in Cultured Sympathetic Neurones Can Be Suppressed at the Posttranslational Level by Nerve Growth Factor, Cyclic AMP, and Depolarization , 1991, Journal of neurochemistry.

[98]  S. Fahn,et al.  Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity , 1993, Annals of neurology.

[99]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[100]  S. Ohta,et al.  Confirmation of the enantiomers of 1-methyl-1,2,3,4-tetrahydroisoquinoline in the mouse brain and foods applying gas chromatography/mass spectrometry with negative ion chemical ionization. , 1990, Biomedical & environmental mass spectrometry.

[101]  R. Ramsay,et al.  Evidence that the inhibition sites of the neurotoxic amine 1-methyl-4-phenylpyridinium (MPP+) and of the respiratory chain inhibitor piericidin A are the same. , 1991, The Biochemical journal.

[102]  B. Hyman,et al.  Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate , 1993, Journal of neurochemistry.

[103]  C. Nathan,et al.  Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells , 1989, The Journal of experimental medicine.

[104]  E. Wolvetang,et al.  Mitochondrial respiratory chain inhibitors induce apoptosis , 1994, FEBS letters.

[105]  B. Rosen,et al.  1‐Methyl‐4‐Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism , 1992, Journal of neurochemistry.

[106]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[107]  R. Ramsay,et al.  Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. , 1986, Biochemical and biophysical research communications.

[108]  K. Takeshige,et al.  1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. , 1990, Biochemical and biophysical research communications.

[109]  R. Ramsay,et al.  Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. , 1986, Life sciences.

[110]  B. Crain,et al.  Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. , 1993, Genomics.

[111]  B Chance,et al.  The cellular production of hydrogen peroxide. , 1972, The Biochemical journal.

[112]  D. Ben-shachar,et al.  Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats , 1991, Journal of neurochemistry.

[113]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[114]  T. Ozawa,et al.  Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson's disease , 1991, Annals of neurology.

[115]  D. Turnbull,et al.  Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease , 1991, Journal of the Neurological Sciences.

[116]  K. Jellinger,et al.  Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.

[117]  B. Ackrell,et al.  Is complex II involved in the inhibition of mitochondrial respiration by N-methyl-4-phenylpyridinium cation (MMP+) and N-methyl-beta-carbolines? , 1993, Biochemical Journal.

[118]  T. Nagatsu,et al.  An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.

[119]  A Hartley,et al.  Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease , 1994, Journal of neurochemistry.

[120]  L. Greene,et al.  Aurintricarboxylic acid rescues PC12 cells and sympathetic neurons from cell death caused by nerve growth factor deprivation: correlation with suppression of endonuclease activity , 1991, The Journal of cell biology.

[121]  F. Hefti,et al.  Toxicity of 1‐Methyl‐4‐Phenylpyridinium for Rat Dopaminergic Neurons in Culture: Selectivity and Irreversibility , 1990, Journal of neurochemistry.

[122]  R. Ramsay,et al.  Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. , 1994, The Journal of biological chemistry.

[123]  F. Di Virgilio,et al.  Mitochondrial DNA is not fragmented during apoptosis. , 1992, The Journal of biological chemistry.

[124]  J. Bus,et al.  Paraquat: model for oxidant-initiated toxicity. , 1984, Environmental health perspectives.

[125]  S. Ohta,et al.  Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. , 1986, Biochemical and biophysical research communications.

[126]  J. Haxby,et al.  Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia. , 1986, Archives of neurology.

[127]  J. Cooper,et al.  Mitochondrial function in Alzheimer's disease , 1993, The Lancet.

[128]  S. Ohta,et al.  Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease , 1990, Journal of the Neurological Sciences.

[129]  J A Helpern,et al.  In vivo 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia , 1989, Neurology.

[130]  C. Marsden,et al.  Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. , 1996, Biochemical pharmacology.

[131]  K. Davies,et al.  The oxidative inactivation of mitochondrial electron transport chain components and ATPase. , 1990, The Journal of biological chemistry.

[132]  K. Ohno,et al.  Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. , 1990, Biochemical and biophysical research communications.

[133]  J. Langston,et al.  Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? , 1985, Life sciences.

[134]  P. Carrupt,et al.  Inhibition of monoamine oxidase by isoquinoline derivatives. Qualitative and 3D-quantitative structure-activity relationships. , 1995, Biochemical pharmacology.

[135]  N. Quinn,et al.  Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period , 1986, Movement disorders : official journal of the Movement Disorder Society.

[136]  P. Allen,et al.  Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle , 1995, Neurology.

[137]  L. Hillered,et al.  Respiratory Activity of Isolated Rat Brain Mitochondria following in vitro Exposure to Oxygen Radicals , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[138]  S. Hodge,et al.  Twin studies and the genetics of Parkinson's disease—a reappraisal , 1990, Movement disorders : official journal of the Movement Disorder Society.

[139]  K. Ohno,et al.  Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease. , 1991, Biochemical and biophysical research communications.

[140]  F. Mettler Choreoathetosis and striopallidonigral necrosis due to sodium azide. , 1972, Experimental neurology.

[141]  Environmental risk factors in Parkinson's disease , 1990, Neurology.

[142]  J. Cooper,et al.  Mitochondrial myopathy with a defect of mitochondrial-protein transport. , 1990, The New England journal of medicine.

[143]  K. Suzuki,et al.  Selective inhibition of complex I of the brain electron transport system by tetrahydroisoquinoline. , 1989, Biochemical and biophysical research communications.

[144]  B. Rosen,et al.  Malonate produces striatal lesions by indirect NMDA receptor activation , 1994, Brain Research.

[145]  J. Schulz,et al.  Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.

[146]  C. Marín,et al.  Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.

[147]  S. Dimauro,et al.  Mitochondria1 involvement in Parkinson's disease , 1993, Neurology.

[148]  J. Casida,et al.  Interaction of 1‐Methyl‐4‐Phenylpyridinium Ion (MPP+) and Its Analogs with the Rotenone/Piericidin Binding Site of NADH Dehydrogenase , 1991, Journal of neurochemistry.

[149]  K. Takeshige,et al.  Alteration of inner-membrane components and damage to electron-transfer activities of bovine heart submitochondrial particles induced by NADPH-dependent lipid peroxidation. , 1982, The Biochemical journal.

[150]  M. Naoi,et al.  Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies , 1996, Brain Research.

[151]  T. Alston,et al.  3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[152]  M. Naoi,et al.  N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins. , 1993, Advances in neurology.

[153]  J. Cooper,et al.  Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement , 1992, Journal of neurochemistry.

[154]  N. Savarese,et al.  Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients , 1993, Neurology.

[155]  H. Reichmann,et al.  Electron transport chain defects in Alzheimer's disease. , 1994, Neurology.

[156]  J. Cooper,et al.  Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. , 1993, Journal of anatomy.

[157]  R. Ramsay,et al.  Relation of superoxide generation and lipid peroxidation to the inhibition of NADH-Q oxidoreductase by rotenone, piericidin A, and MPP+. , 1992, Biochemical and biophysical research communications.

[158]  J. Cooper,et al.  Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion. , 1993, American journal of human genetics.